LBPS 01–05 GANODERMA LUCIDUM POLYSACCHARIDE PEPTIDES AS ANTIOXIDANT, ANTI-INFLAMMATION, ANTI-HYPERTENSION AND ANTI-LIPID IN HIGH-RISK PATIENTS OF ATHEROSCLEROSIS. (September 2016)

• Record Type: Journal Article
• Authors: Handayani, Olivia; Sargowo, Djanggan; Siwi, Kartika; Ubaidillah, Nizamuddin; Widya, Adriyawan; V, Vitriyaturrida
• Is Part Of: Journal of hypertension. Volume 34:(2016) Supplement 1
• Publication Date: 2016-09
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000500375.59205.d7
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objective: Ganoderma lucidum is a type of mushroom that has been used for thousands years throughout Asia. It is known to demonstrate numerous health benefiting properties including antioxidant, anti-inflammation, anticancer effects, hypoglycemic and blood cholesterol reducing properties. This research was conducted to determine the efficacy of Ganoderma lucidum polysaccharide peptides (PSP) as anti-inflammation and antioxidant in cardiovascular disease Design and Method: This is a prospective study with pre-test and post-test design of 37 high-risk patients of cardiovascular disease based on the Framingham Risk Score that was conducted for 3 months. Patients were advised to consume PSP 3×250 mg as an adjuvant to their previous medications. The primary endpoint was the change in cholesterol levels, blood pressure and antioxidant markers. Results: The administration of PSP 3x250 mg could reduce total cholesterol level by 3.48 ± 46.9 mg/dl (p = 0.672). Both pre- and post-test of total cholesterol are significantly correlated (r = 0.618, p = 0.000). PSP administration, however, increased the level of HDL cholesterol by 7.84 ± 10.79 (p = 0.000). The systolic blood pressure decreased from 130.14 ± 43.37 mmHg to 118.24 ± 55.68 (p = 0.109), and the diastolic blood pressure decreased from 80 ± 25.74 mmHg to 73.24 ± 33.85 mmHg (p = 0.102). Despite a great reduction of blood pressure to normal range, it was not statistically significant. The reduction of anti-inflammatory markers interleukin-6 (IL-6), from 279.75 ± 120.76 to 29.32 ± 26.44 (p = 0.000) and TNF alpha, from 13447.84 ± 2199.46 to 544.85 ± 292.06 (p = 0.000) were significant. Malondialdehyde (MDA) level also decreased significantly with PSP treatment for 3 months (p = 0.000). Conclusions: The administration of polysaccharide peptides of Ganoderma lucidum for three months in high-risk patients with hypertension can reduce the blood pressure within normal range, improve total cholesterol level and significantly play role as anti-inflammation and antioxidant in cardiovascular disease.